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The anti-emetic potential of the 5-hydroxytryptamine3 receptor
antagonist BRL 43694
J. Bermudez, E.A. Boyle, W.D. Miner & G.J. Sanger
Beecham Pharmaceuticals Research Division, Coldharbour Road, The Pinnacles, Harlow, Essex CMI9 5AD, UK.
Summary In ferrets, the selective 5-hydroxytryptamine (5-HT) 5-HT3 receptor antagonist BRL 43694 given
as a single injection (0.05-0.5 mg kg- 1 i.v.) before cisplatin, or by divided dose (2 x 0.005-2 x 0.5 mgkg- I i.v.)
before and after cisplatin dramatically reduced or abolished the severe cisplatin-induced vomiting. BRL 43694
also substantially reduced the vomiting induced by cyclophosphamide: doxorubicin, and prevented the
trimelamol-induced emesis. The severe emesis caused by whole body exposure to X-irradiation was prevented
by intravenous or oral BRL 43694. A single i.v. dose of BRL 43694 given during an emetic episode or within
the peak emetic period, abolished the vomiting induced by the cytotoxic drugs and by X-irradiation, usually
within 30s. Where the induction of emesis was prevented or subsequently abolished by BRL 43694, the
associated behaviour (subjectively assessed as nausea) was also absent or greatly attenuated. BRL 43694
(0.1 mg kg- 1 i.v.) did not affect the emesis evoked in dogs by the dopamine agonist apomorphine. The potent
anti-emetic activity of BRL 43694 is discussed in terms of potential clinical use, and of the fundamental role
that 5-HT3 receptors may play in the mechanisms of nausea and vomiting.
High intravenous doses of metoclopramide (Maxolon; Bee-
cham Pharmaceuticals) are used in the management of
nausea and vomiting in man. Miner and Sanger (1986) and
Miner et al. (1987) have shown in ferrets that high doses of
metoclopramide could reduce or prevent the emetic response
to cisplatin or cyclophosphamide and doxorubicin by virtue
of its antagonism of 5-hydroxytryptamine (5-HT) 5-HT3
receptors. These effects of metoclopramide were therefore
mediated neither by dopamine receptor antagonism nor by
the ability of metoclopramide to stimulate gut motility. The
present work now describes the anti-emetic activity, in
ferrets, of a considerably more potent, efficacious and selec-
tive 5-HT3 receptor antagonist, BRL 43694 (Fake et al.,
1987). In contrast to metoclopramide, BRL 43694 does not
normally stimulate gastric motility and does not antagonise
dopamine receptors. BRL 43694 may therefore have advan-
tages not only in potency, but also in its selectivity and its
efficacy as an anti-emetic drug. Preliminary results were
presented to the British Association for Cancer Research and
to the British Pharmacological Society (Boyle et al.,
1987a,b).
Materials and methods
Animals
Male polecat or albino ferrets, 1-2kg, were housed singly,
with free access to food (SDS Diet B) and water. Ferrets
from different suppliers were used, and these showed no
obvious differences in their responses to emetic stimuli or to
BRL 43694. Upon completion of an experiment the ferrets
were killed by an overdose of euthatal (May and Baker).
For convenience, beagle dogs, 12-18 kg of either sex, were
used for the experiments with apomorphine. Chronic intra-
venous cannulae were not required and since cytotoxic
therapy was not administered, the animals were not subse-
quently sacrificed.
Procedures
Surgery As detailed previously (Miner & Sanger, 1986;
Miner et al., 1987), a modification of the technique described
by Florczyk and Schurig (1981) was used for jugular vein
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cannulation and the insertion of arterial valves. Ketamine
hydrochloride (Vetalar, Parke-Davis; 40mg kg-1 i.m.) was
given prior to anaesthesia under halothane; N20:02. Peni-
cillin (30,000 U Lentrax, i.m.; May and Baker) was given
after surgery. Following completion of surgery, 3-4 days
recovery was allowed before further experimentation.
Induction of emesis Emesis was induced by i.v. injection of
cisplatin (10mg kg-1), or cyclophosphamide (80mg kg-1)
with doxorubicin (6mg kg-1), or by intraperitoneal (i.p.)
injection of trimelamol (50mg kg-1). For trimelamol, the i.p.
route of injection was preferred over the i.v. route because
dimethylsulphoxide (DMSO) was required as the solvent.
These doses of cytotoxic drugs were the lowest required to
cause repeated and reproducible vomiting. In the experi-
ments with dogs, apomorphine (0.1 mg kg-1) was injected
subcutaneously.
To evoke emesis by X-irradiation, ferrets were closely
confined in a ventilated box constructed of perspex 1 mm
thick. X-rays were derived from the tungsten anode of a
Machlett Model OEG-50 X-ray supply, operating at 50kV
and 20mA through a berylium window with a 0.18mm
aluminium filter and placed about 25cm above the ferret.
This low energy X-ray beam was just sufficient to cause
reproducible emesis; exposure time was 10.4 min.
Observations Ferrets given cisplatin or cyclophosphamide
and doxorubicin were observed for the onset of emesis
(latency period) and the number of emetic episodes over
240 min after injection. Emesis had usually ceased in control
animals within this period. The observation period following
trimelamol was 210min, minimising any discomfort caused
by the i.p. injection of the large volume of trimelamol and
solvent. For dogs given apomorphine, the observation period
was 30min. The observation period following X-irradiation
was 120 min, since in control animals, emesis had ceased
within this time. Untreated ferrets were observed for
240 min.
In some experiments, additional behavioural events were
also monitored, these being subjectively considered to indi-
cate 'nausea'. These events were retching, drinking, defeca-
tion, posturing to defecate, urgent tunnelling under the wood
shavings in the pen (burrowing), obtrusive licking (saliva-
tion?), and urgent backing movements (backing). Behaviours
such as playing, foraging, casual burrowing, sleeping, or
occasional urgent grooming were observed in control ferrets
and were therefore not recorded. All experiments were
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performed between 0800 and 1400 h, with the same two
observers throughout.
Drugs Cisplatin (Neoplatin for injection; Bristol Myers),
cyclophosamide (Endoxana for injection; WB Pharma-
ceuticals) and doxorubicin (Adriamycin for injection; Farmi-
talia) were diluted in water for injection, BP. Trimelamol
(N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine;
kindly provided by Dr. I. Judson, Institute of Cancer
Research, London, UK) was dissolved in DMSO: 5% dex-
trose [1: 10]. Apomorphine hydrochloride was dissolved in
0.05% w/v sodium metabisulphite solution. BRL 43694 (endo
- N - (9 - methyl - 9 - azabiocyclo[3.3.l]non - 3 - yl) - 1 -
methyl - 1H - indazole - 3 - carboxamide hydrochloride;
Beecham Pharmaceuticals) was dissolved in water for injec-
tion BP or 0.9% saline. Doses of BRL 43694 are given as
mg kg- free base.
Statistical analysis Results are given as means + s.e.m. and
were analysed using Student's t test. In the Figures, the
standard error bars have been omitted for clarity.
Results
The number of ferrets exposed to emetic stimuli in the
absence of anti-emetic therapy was minimised by testing at
least one ferret, chosen at random, from each delivery of
animals. These ferrets provided the accumulated control data
described below.
Emesis evoked by cisplatin
The mean number of emetic episodes for each 10 min period
over the 240min following injection of cisplatin is shown in
Figure 1. When BRL 43694 was given in divided dose,
0.5mg kg- 1 i.v., 30 min before and 45 min after cisplatin,
emesis was prevented (Figure 1; Table I). BRL 43694 gave a
dose-related protection against cisplatin-induced emesis down
to a dose of 2 x 0.005mg kg-1 i.v. (Table I). Even at this
lowest dose there was a highly significant delay in the
average onset of emesis (P<0.001), with 2 of the 4 ferrets
being completely protected.
A single injection of BRL 43694 given 15 min before
cisplatin, also dose-dependently reduced the number of
emetic episodes (Table I). There was complete protection
with 0.5 mg kg-1 i.v., and significantly less vomiting than in
unprotected ferrets at 0.05 mg kg-1 i.v. In the experiments
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Figure 1 Cisplatin-induced emesis in the ferret. (a) Emetic epi-
sodes (mean values) shown in 10min intervals over 240min after
cisplatin (10mg kg-1 i.v.) at time zero [arrow], with saline given
at -30 and +45min as shown (A); (n=8). (b) Protection from
emesis by BRL 43694 (2 x 0.5mg kg- I i.v.) given at -30 and at
+45min as shown (A); (n=4). (c) Abolition of vomiting by BRL
43694 (0.5mgkg-I i.v.) given during emesis (V); (n=4).
with BRL 43694 0.5mgkg-1 i.v., behavioural changes were
also monitored and compared with the behaviour of
untreated ferrets (Figure 2). Cisplatin-evoked emesis was
Table I Cisplatin-induced vomiting in the ferret
Anti-emetic
treatment
(mgkg- I i v.)
(a) Divided dose of BRL 43694
Cisplatin 2 x Saline
Cisplatin
(b) Single
Cisplatin
BRL 43694
0.5/0.5
BRL 43694
0.05/0.05
BRL 43694
0.005/0.005
dose of BRL 43694
BRL 43694
0.5
BRL 43694
0.05
Emetic
stimulus
(i.v.)
Latency period
to first vomit
(min)
71.0 +2.8
(n=8)
No vomits
(n =4)
230.5 +9.5b
(n =4)
183.8 +32.6b
(n =4)
No vomits
(n=4)
141.0+ 50.1
(n=3)
Number of
emetic episodes
(over 240min)
16.3+ 1.7
ob
0.5 + 0.5
1.0+0.6
a
ob
3.7+ 1.9a
Ferrets were given cisplatin 10mgkg-I i.v. BRL 43694 was given (a)
30min before and 45min after cisplatin or (b) 15 min before cisplatin.
Compared with controls, aP<0.01; bP<0.001. If a ferret did not vomit,
latency period was taken as equal to the observation period (240min).
Results are given as means+s.e.m.
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Figure 2 Selected patterns of behaviour of two untreated ferrets
monitored over 240min, with each event being represented by a
vertical line. Similar patterns of behaviour were observed in two
further ferrets (female) monitored over the same period (results
not shown). (defec.) denotes posture to defecate.
accompanied or preceded by prolonged bouts of retching;
backing and less frequently, burrowing, accompanied these
events. Most of the animals drank occasionally. Three of the
four cisplatin-treated animals which received BRL 43694,
showed near-normal behaviour (Figure 3), with drinking
being the main significant event. The fourth animal had a
cluster of burrowing and retching towards the end of the
observation period (180-190 min) but this was not accom-
panied by emesis.
Once cisplatin-induced emesis was established (90 min after
injection), a single dose of BRL 43694 (0.5mg kg- 1 i.v.),
given during an emetic episode, abolished further emesis
usually within 30s after injection (Figure 1). Thereafter, the
ferrets were protected from further emesis.
Emesis evoked by cyclophosphamide and doxorubicin
The mean number of emetic episodes for each 10 min period
following injection of cyclophosphamide and doxorubicin is
shown in Figure 4. BRL 43694 given in divided dose,
0.5mg kg-1 i.v. 30 min before and 30min after the cytotoxic
drugs, completely prevented emesis in one ferret, and greatly
reduced emesis (1, 1 and 2 episodes respectively) in the other
3 ferrets (Figure 4). Behavioural changes associated with
emesis were not measured in these experiments.
Once emesis was established, a single dose of BRL 43694
(0.5mgkg-1 i.v.) given during an emetic episode (at 50min
or 80 min, following cytotoxic drug injections) abolished
emesis, usually within 30s after injection (Figure 4). There-
after, the ferrets were protected from further emesis.
Emesis evoked by trimelamol
There was considerable variation in the emetic response to
trimelamol, with the onset of emesis ranging from 6min to
80min after injection; the mean time of onset of emesis is
shown in Table II. Two control ferrets injected with an
equivalent volume of 10% DMSO in 5% dextrose did not
vomit (Table II) and appeared unaffected by this treatment.
BRL 43694 prevented emesis (Table II) and associated
behavioural disturbances (Figure 5) when given in divided
dose, 0.5mg kg- i.v. 30min before and 45 min after
trimelamol.
Emesis evoked by X-irradiation
There was a rapid and uniform response to X-irradiation in
control animals, with emesis usually occurring within 20 min
of the start of exposure and remaining severe for -1 h
(Figure 6). BRL 43694 (0.5mgkg-1i.v.) given 5min before
exposure, prevented vomiting in all 4 ferrets tested (Figure
6). Compared with untreated ferrets, the behavioural changes
associated with emesis were also prevented by this dose of
BRL 43694 (Figure 7).
BRL 43694 (0.5mgkg-1 i.v.) given to ferrets during the
peak emetic period (-20min after the removal from the X-
ray source), prevented subsequent emesis (Figure 6) and
associated behavioural changes (Figure 8).
Oral administration of BRL 43694 (0.5mgkg-1) 60min
before irradiation abolished emesis in 2 of 3 ferrets, and
considerably delayed its onset in the third (a mean value is
shown in Table III). There was still some delay in onset at a
tenth of this dose of BRL 43694 (0.05mg kg-1), as well as a
reduction in the number of emetic episodes (Table III).
Emesis evoked by apomorphine
BRL 43694 0.1 mg kg- I i.v. given 15 min before apomor-
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Figure 3 Selected patterns of behaviour evoked by cisplatin (10mg kg - i.v.) in control ferrets (n =8) and in treated ferrets given
BRL 43694 (0.5mgkg-I i.v.; n=4) 15min before cisplatin. The behavioural events (each represented by a vertical line) were
monitored over 240min after dosing with cisplatin (10mgkg-l i.v.) at time zero. (defec.) denotes posture to defecate.
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Figure 4 Emesis induced by cyclophosphamide and doxorubicin
in the ferret. (a) Emetic episodes (mean values) shown in 10min
intervals over 240min after cyclophosphamide (80mg kg- i.v.)
and doxorubicin (6 mg kg- 1 i.v.) given at time zero (arrow), with
saline given at -30 and +30min as shown (A); (n =7). (b)
Protection from emesis by BRL 43694 (2 x 0.5 mg kg- I i.v.) given
at -30 and +30min as shown (A); (n =4). (c) Abolition of
vomiting in 2 ferrets by BRL 43694 (0.5mg kg- i.v.) given
during emesis as shown (V); (n=4).
phine did not protect the dogs against the subsequent emesis.
The number of vomits evoked by apomorphine in dogs
injected with saline (9.5 +2.5 vomits) was not significantly
different when BRL 43694 was injected (9.3 +2.9 vomits;
n =4).
Discussion
Our results show that BRL 43694 is a highly potent and
efficacious anti-emetic in the ferret, whether the stimulus is
one of a number of severely emetogenic cytotoxic drugs or
exposure to X-irradiation. We have previously demonstrated
that results obtained with other anti-emetic drugs in ferrets
can correlate with their anti-emetic potential in patients
(Miner et al., 1987). Our present work with BRL 43694
therefore suggests that this compound may provide consider-
able relief for cancer patients undergoing therapy. Further-
more, they provide yet more evidence in support of our
original proposal for a crucial involvement of 5-HT3 recep-
tors in the mechanisms of severe emesis (Miner et al., 1986;
Miner & Sanger, 1986).
In contrast to similar experiments in ferrets, using high
doses of metoclopramide (Miner et al., 1987), in which
emesis was simply reduced, BRL 43694 prevented emesis
when given either prophylactically (i.v. or p.o.) or after
emesis had begun. In the latter experiments, a single dose of
BRL 43694, given at a peak emetic period and during emesis
itself, dramatically abolished vomiting within seconds on
every occasion of testing. BRL 43694 may, therefore, have
considerable flexibility within the clinic, abolishing emesis
whenever it is used.
During the course of monitoring emetic episodes, it
became obvious that a record of emesis alone undervalued
the experiments. Emesis was always accompanied by marked
disturbances in behaviour, and this has been demonstrated
previously for tetralin-evoked emesis in-marmosets (Costall
et al., 1986a). In the present >Ixperiments with ferrets,
retching could occur in the absence of vomiting (or vice
versa), and was frequently preceded or accompanied by
urgent burrowing and backing, with which it was clearly
associated. Initially it was thought that frequent defaecation
or posturing to defaecate might be an index of general
intestinal disturbance and discomfort in unprotected ferrets
receiving the emetic stimuli, but this could not be demon-
strated here; likewise tongue protrusion or licking were
monitored as a reflection of the salivation experienced in
human nausea, but again, they did not accompany emesis in
these experiments. In general, the different emetic stimuli
evoked behavioural disturbances in waves, usually culminat-
ing in emesis, and reminiscent of the human condition of
nausea. Whether these findings equate with human nausea or
not, for the ferret they clearly portray considerable restless-
ness and discomfort closely associated with emesis. That this
can be prevented, by either prophylactic or intervention
treatment with BRL 43694, implies that 5-HT3 receptors
may also be involved in the nausea associated with aggres-
sive anti-cancer therapies in the clinic.
We have previously shown that 5-HT3 receptors may be
involved in the mechanisms of emesis evoked by cisplatin
(Miner & Sanger, 1986; Miner et al., 1986, 1987), cyclo-
phosphamide (Andrews et al., 1987b), cyclophosphamide
plus doxorubicin (Miner et al., 1987) or by total body X-
irradiation (Andrews et al., 1987; Miner et al., 1987). Similar
conclusions have also been reached by others in ferrets
(Costall et al., 1986b; 1987; Andrews et al., 1987a; Hawthorn
et al., 1988) and in cancer patients receiving cisplatin
(Leibundgut & Lancranjan, 1987; Carmichael et al., 1988)
and non-cisplatin cytotoxic therapy (Cunningham et al.,
Table II Trimelamol-induced vomiting in the ferret
Emetic Anti-emetic Latency period Number of
stimulus treatment to first vomit emetic episodes
(i.p.) (mgkg'- i.v.) (min) (over 210min)
DMSO/dextrose None 35.8+16 12.3+2.8
+trimelamol (n=4)
DMSO/dextrose BRL 43694 No vomits ob
+trimelamol 0.5/0.5 (n =3)
DMSO/dextrose None No vomits ob
(n =2)
Ferrets were given trimelamol 50mgkg-1 i.p. BRL 43694 (0.5mgkg-1) was
given 30min before and 45min after trimelamol. Compared with controls
aP<0.05 bp<0.0Ol Results are given as means+s.e.m.
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Figure 5 Selected patterns of behaviour evoked by trimelamol
(50 mg kg-1 i.p.) in control ferrets (n=4) and in treated ferrets,
given BRL 43694 (2 x 0.5 mg kg- 1 i.v.; n =3) 30min before and
45 min after trimelamol. The behavioural events (each repre-
sented by a vertical line) were monitored over 210min after
dosing with trimelamol at time zero. (defec.) denotes posture to
defecate.
1987). We now show that 5-HT3 receptors may also be
involved in the mechanisms of emesis evoked by trimelamol,
a potentially useful anti-cancer drug (see Rutty et al., 1986).
In cancer patients, the emesis caused by trimelamol can be
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Figure 6 Radiation-induced emesis in the ferret. (a) Emetic
episodes (mean values) shown in 10min intervals over 120min
after exposure to X-irradiation from 0 to 10.4min (arrow);
(n= 5). (b) Protection from emesis by BRL 43694 (0.5mgkg-I
i.v.) given at -5min as shown (A); (n=4). (c) Abolition of
vomiting by BRL 43694 (0.5mg kg-1 i.v.) given immediately
after an emetic episode had occurred (V); (n=4).
severe and dose-limiting, discouraging a more widespread
use. The advantages of concurrent use of BRL 43694 with
severely emotogenic anti-cancer drugs are therefore obvious,
illustrating how the current use of such drugs might change
with the advent of very effective antiemetic agents.
BRL 43694 is a selective 5-HT3 receptor antagonist with
little or no affinity for a wide range of receptors other than
the 5-HT3 receptor (Fake et al., 1987). In particular, BRL
43694 does not antagonise dopamine D2 receptors, and
therefore should be free of the extrapyramidal side-effects
associated with high intravenous doses of metoclopramide.
Consistent with the poor affinity for D2 receptors is the
failure of BRL 43694 to antagonise apomorphine-evoked
emesis in dogs. Although we have not demonstrated a
similar lack of activity in ferrets, these experiments do
suggest that BRL 43694 may not suppress the entire emetic
reflex, but more specifically block those stimuli that evoke
emesis by acting through a 5-HT3 receptor-mediated mechan-
ism. It is thought that these 5-HT3 receptors are located on
visceral afferent nerve terminals within the abdomen and
also at an 'extra-abdominal' site (Andrews & Hawthorn,
1987). The latter 5-HT3 receptor site is not yet precisely
defined, but may be located within the area postrema,
containing the emetic chemoreceptor trigger zone. Thus, the
ability of drugs or radiation to cause emesis, and their
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Figure 8 Patterns of behaviour in ferrets given a single dose of
BRL 43694 (0.5mg kg 1 i.v.; n=2) immediately after a group of
emetic episodes and during the peak emetic period following X-
irradiation (arrow). The behavioural events (each represented by
a vertical line) were monitored over 120min from the start of X-
irradiation (10.4min; shaded band). (defec.) denotes posture to
defecate.
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Figure 7 Selected patterns of behaviour evoked by X-irradiation
in control ferrets (n=4) and in treated ferrets, given BRL 43694
(0.5mg kg- i.v.; n =2) 15min before X-irradiation. The be-
havioural events (each represented by a vertical line) were
monitored over a 120min observation period following X-
irradiation (10.4min exposure; shaded band). (defec.) denotes
posture to defecate.
respective latency periods, could depend on their potential to
increase the release and/or synthesis of 5-HT. For example,
in small laboratory animals (which do not vomit), total body
X-irradiation may cause a sudden release of 5-HT from the
gut, depleting the mucosal enterochromaffin cells of the
5-HT which they normally contain (Matsouka et al., 1962).
The released 5-HT could therefore activate gastrointestinal
and/or hepatic primary afferent fibres, which eventually
synapse within the area postrema. Whole body or head
irradiation of rats may also increase 5-HT synthesis within
the lower brain stem (Altman et al., 1970). A sustained
increase of 5-HT synthesis within the brainstem might
therefore be expected to cause emesis by a more direct action
at the area postrema.
For cytotoxic drugs, there has been little or no previous
association with 5-HT. Gunning et al. (1987) described an
increase in 5-HT and 5-hydroxyindoleacetic acid (5-HIAA)
extracted from the small intestinal mucosa of ferrets pre-
viously injected with cisplatin (9 mg kg 1 i.p. for 2 days);
there was no change in the amount of 5-HT extracted from
the gastric mucosa or from the hypothalamus. Furthermore,
cisplatin was shown to cause selective damage of the small
intestine, but not the stomach. However, although these
results support the involvement of 5-HT in the mechanisms
of emesis, the measurements of 5-HT and 5-HIAA were
made after emesis should have occurred. Since mechanical
stimuli can release 5-HT from the gut (Bennett et al., 1966),
these particular changes in 5-HT release cannot, therefore,
necessarily be taken as evidence for an association between
5-HT and the emetic potential of cisplatin.
In contrast to metoclopramide, interdigestive gastric moti-
lity is not normally stimulated by BRL 43694 (Fake et al.,
1987). The ability of metoclopramide to stimulate gastro-
intestinal motility may provoke diarrhoea in up to 25% of
cancer patients receiving the drug in combination with
Table III Radiation-induced vomiting in the ferret
Anti-emetic Latency period Number of
Emetic treatment to first vomit emetic episodes
stimulus (mgkg- I p.o.) (min) (over 120min)
X-irradiation Saline 21.0+0.8 26.0 + 3.5
(n=7)
X-irradiation BRL 43694 104.7+ 15.3b 2.3 +2.3a
0.5 (n=3)
BRL 43694 51.8+6.3b 6.3+2._1a
0.05 (n =4)
Ferrets were X-irradiated for 10.4min. BRL 43694 was given orally 60min
before the start of irradiation. Compared with controls, ap<0.01; bp<0.001. If a
ferret did not vomit, latency period was taken as equal to the observation period
(120min). Results are given as means+s.e.m.650 J. BERMUDEZ et al.
cytotoxic agents (Strum et al., 1982). Selective 5-HT3 recep-
tor antagonists such as BRL 43694 may therefore
be expected to have minimal problems associated with
diarrhoea and abdominal cramps.
In conclusion, our experiments with BRL 43694 in ferrets
demonstrate the remarkable anti-emetic potential of this
compound. Furthermore, since BRL 43694 can also prevent
the behavioural changes which are associated with emesis in
ferrets, both nausea and emesis may be prevented by this
compound. BRL 43694 is therefore currently undergoing
clinical trials in cancer patients. Early results with BRL
43694 show a promising anti-emetic and anti-nauseant
activity against cisplatin-containing therapies, when dosed
prophylactically (Carmichael et al., 1988; Cassidy et al.,
1988; Gumbell et al., 1988) or after emesis has begun
(Cassidy et al., 1988). BRL 43694 did not cause extra-
pyramidal symptoms and was free of the sedation and other
side effects detected with dopamine receptor antagonists,
benzodiazepine or corticosteroid treatments. It is therefore
hoped that the use of this drug will allow effective manage-
ment of the debilitating nausea and vomiting associated with
aggressive anti-cancer therapy.
We thank Mr R. Collie and Mrs V. Smith for assistance with the
ferret cannulations and Mr. G. Heald for his radiation expertise. We
are also grateful to Dr G. Rapeport and Dr I. Judson for suggesting
the studies with trimelamol.
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